- Home
- DGICB vs LAB Comparison
DGICB vs LAB Comparison
Compare DGICB & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICB | LAB |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.0M | 488.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | DGICB | LAB |
|---|---|---|
| Price | $15.58 | $1.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 2.1K | ★ 1.5M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | ★ 219.91 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $987,826,105.00 | $169,737,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | 0.89 | ★ 79.77 |
| 52 Week Low | $13.19 | $0.92 |
| 52 Week High | $20.46 | $1.72 |
Technical Indicators
Market Signals| Indicator | DGICB | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 44.14 |
| Support Level | $15.26 | $1.50 |
| Resistance Level | $16.43 | $1.67 |
| Average True Range (ATR) | 0.36 | 0.10 |
| MACD | -0.25 | -0.01 |
| Stochastic Oscillator | 12.21 | 8.48 |
Price Performance
Historical ComparisonAbout DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.